Across TCGA pan-cancer cohorts, SLC22A6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC22A6 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLC22A6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC22A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BRCA, and LGG are the cancer types where SLC22A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.829	.016	12	view →
BRCA	OS	Median	III,IV	0.157	0.906	<.001	12	view →
LGG	DFS	Median	All	0.068	0.833	<.001	6	view →
ESCA	DFS	Median	III,IV	0.103	0.442	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SLC22A6 tumor-vs-normal RNA expression · all SLC22A6 data types